Biorestorative Therapies (BRTX) vs. Its Rivals Critical Comparison

Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Biorestorative Therapies to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, dividends, earnings, valuation and risk.

Risk and Volatility

Biorestorative Therapies has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Biorestorative Therapies’ rivals have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Biorestorative Therapies and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biorestorative Therapies 1 1 0 0 1.50
Biorestorative Therapies Competitors 9924 15318 45696 1603 2.54

As a group, “Biotechnology” companies have a potential upside of 131.86%. Given Biorestorative Therapies’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Biorestorative Therapies has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Biorestorative Therapies and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Biorestorative Therapies $357,870.00 -$14.24 million -0.07
Biorestorative Therapies Competitors $715.40 million $10.31 million -18.32

Biorestorative Therapies’ rivals have higher revenue and earnings than Biorestorative Therapies. Biorestorative Therapies is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Biorestorative Therapies and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biorestorative Therapies -3,088.27% -508.42% -230.94%
Biorestorative Therapies Competitors -12,319.70% -407.93% -30.95%

Summary

Biorestorative Therapies rivals beat Biorestorative Therapies on 8 of the 13 factors compared.

About Biorestorative Therapies

(Get Free Report)

BioRestorative Therapies, Inc. is a biotechnology company developing cell-based treatments for medical conditions with limited treatment options. Its work focuses primarily on regenerative medicine and uses adult stem cells in research and product development. The company’s lead program, BRTX-100, is an investigational treatment made from a patient’s own cultured bone marrow-derived mesenchymal stem cells. It is being developed for chronic lumbar disc disease. BioRestorative also researches its ThermoStem platform, which uses brown adipose-derived stem cells in programs aimed at metabolic and related disorders.

Receive News & Ratings for Biorestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biorestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.